FIELD: biotechnology; medicine.
SUBSTANCE: invention discloses a vector based on a genetically modified herpes simplex virus type 1, which makes it possible to obtain an isolated monoclonal antibody that specifically binds to PD-1 with increased affinity.
EFFECT: invention can be used in medical practice as a medicinal product to suppress the growth of tumor cells in the treatment of various cancers.
8 cl, 2 dwg, 12 tbl, 10 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HIGH-AFFINITY ANTI-PD-1 AND ANTI-LAG-3 ANTIBODIES AND BISPECIFIC BINDING PROTEINS OBTAINED FROM THEM | 2019 |
|
RU2782381C2 |
| IMMUNOCYTOKINES AND THEIR USE | 2021 |
|
RU2818371C1 |
| ANTIBODIES TO PD-1 AND THEIR APPLICATION | 2017 |
|
RU2761640C2 |
| ANTI-PD-L1 AND IL-2 CYTOKINES | 2017 |
|
RU2769282C2 |
| PD-L1 SPECIFIC ANTIBODIES | 2017 |
|
RU2756236C2 |
| NEW ANTIBODY COMPOSITIONS FOR CANCER IMMUNOTHERAPY | 2019 |
|
RU2804490C2 |
| ANTIBODIES AGAINST SIGNAL-REGULATORY ALPHA PROTEIN AND THEIR APPLICATION METHODS | 2017 |
|
RU2771964C2 |
| IMMUNOGLOBULIN WITH TANDEM FAB- FRAGMENTS AND ITS APPLICATION OPTIONS | 2017 |
|
RU2767329C2 |
| BISPECIFIC ANTIBODY | 2020 |
|
RU2814713C2 |
| BISPECIFIC ANTIGEN-BINDING MOLECULES CONTAINING ANTI-FAP CLONE 212 | 2019 |
|
RU2799429C2 |
